| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Schepens Eye Research Institute, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts.
PURPOSE. To determine whether naive T cells activated in vitro by antigen-pulsed, transforming growth factorß (TGFß)–treated antigen presenting cells (APCs) acquire the capacity to suppress the induction and expression of delayed hypersensitivity in vivo.
METHODS. Naive ovalbumin (OVA)-specific T cells from DO11.10 Tcr transgenic mice
were stimulated in vitro with OVA-pulsed TGFß2-treated APCs. The
cultured cells were harvested and assayed for in vitro production of
mature TGFß. Similar cells were coinjected with primed OVA-specific
BALB/c T cells plus OVA-pulsed APCs into ear pinnae of normal BALB/c
mice (assay for delayed hypersensitivity expression) or coinjected with
OVA-pulsed APCs into footpads of naive DO11.10 mice whose draining
lymph node cells were harvested 4 days later and assayed in vitro for
capacity to secrete interferon-
(IFN-) and interleukin-4 (IL-4)
when stimulated with OVA (assay for induction of delayed
hypersensitivity).
RESULTS. DO11.10 T cells activated in vitro by OVA-pulsed TGFß2-treated APCs
secreted large amounts of mature TGFß and suppressed the expression
of delayed hypersensitivity in a local adoptive transfer assay.
Suppression was reversed in the presence of neutralizing anti-TGFß
antibodies. In addition, in vitro generated regulatory T cells
influenced naive T cells in DO11.10 mice that were responding to an
initial immunization with OVA to secrete IL-4, rather than IFN-.
This influence was independent of TGFß.
CONCLUSIONS. OVA-pulsed APCs, pretreated in vitro with TGFß2, activate DO11.10 T cells in a manner that endows the responding cells with the capacity to suppress the induction and then the expression of delayed hypersensitivity in vivo. In certain ways, these properties of in vitro–activated DO11.10 T cells resemble the properties of afferent and efferent regulatory T cells typically found in the spleens of animals with anterior chamber–associated immune deviation.
This article has been cited by other articles:
|
|
 |
|
  S. Masli, B. Turpie, and J W. Streilein Thrombospondin orchestrates the tolerance-promoting properties of TGF{beta}-treated antigen-presenting cells Int. Immunol., May 1, 2006; 18(5): 689 - 699. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Keino, S. Masli, S. Sasaki, J. W. Streilein, and J. Stein-Streilein CD8+ T Regulatory Cells Use a Novel Genetic Program that Includes CD103 to Suppress Th1 Immunity in Eye-Derived Tolerance. Invest. Ophthalmol. Vis. Sci., April 1, 2006; 47(4): 1533 - 1542. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Keino, M. Takeuchi, T. Kezuka, T. Hattori, M. Usui, O. Taguchi, J. W. Streilein, and J. Stein-Streilein Induction of Eye-Derived Tolerance Does Not Depend on Naturally Occurring CD4+CD25+ T Regulatory Cells. Invest. Ophthalmol. Vis. Sci., March 1, 2006; 47(3): 1047 - 1055. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Streilein Ocular immune privilege: the eye takes a dim but practical view of immunity and inflammation J. Leukoc. Biol., August 1, 2003; 74(2): 179 - 185. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Masli, B. Turpie, K. H. Hecker, and J. W. Streilein Expression of Thrombospondin in TGF{beta}-Treated APCs and Its Relevance to Their Immune Deviation-Promoting Properties J. Immunol., March 1, 2002; 168(5): 2264 - 2273. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
